Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNT2130
- Development stage
- Phase 1
- Lead developer
- Centaurus Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CNT2130 is a small-molecule, once-daily oral inhibitor of dihydroceramide desaturase 1 (DES1), developed by Centaurus Therapeutics. DES1 is the enzyme responsible for the final step of de novo ceramide synthesis, converting dihydroceramide to ceramide. By inhibiting DES1, CNT2130 aims to reduce excess ceramide production and restore lipid balance in tissues, which is hypothesized to address the underlying pathology of cardio-kidney-metabolic (CKM) diseases. Preclinical studies have shown therapeutic activity across kidney, cardiac, hepatic, and metabolic endpoints. It is currently being evaluated in early-phase clinical trials, including a single ascending dose (SAD) study in healthy volunteers, with a primary focus on diabetic nephropathy.
02
Targets
DEGS1 (Delta(4)-desaturase, sphingolipid 1)
Beyond the preview
Go deeper on CNT2130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNT2130.